Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary MethylGene Announces the Appointment of Dr. Charles M. Baum as President and CEO and Changes to The Board Of Directors View HTML
Toggle Summary MethylGene Announces Cdn.$26.1 Million Private Placement
NOT FOR DISSEMINATION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
View HTML
Toggle Summary MethylGene Presents MGCD265 Data at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics View HTML
Toggle Summary MethylGene to Present MGCD265 Data at The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics View HTML
Toggle Summary MethylGene Announces Presentation of MGCD290 Phase I Clinical Data at Idweek™ 2012 View HTML
Toggle Summary MethylGene Provides Clinical Update on its MGCD290 Novel Antifungal Therapeutic Program
Phase I Data to be Presented at the 2012 IDWeek
View HTML
Toggle Summary MethylGene Presents Clinical Data on MGCD265 at The European Society For Medical Oncology (ESMO) 2012 Congress
Three Posters Provide Updates on Monotherapy, Combination Therapy and Healthy Volunteer Trials
View HTML
Toggle Summary MethylGene Announces Change of President and CEO View HTML
Toggle Summary MethylGene Presents MGCD290 Data at The 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) View HTML
Toggle Summary MethylGene to Present MGCD290 Data at The 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) View HTML